Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX: Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
moreShow MRTX Financials
Recent trades of MRTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MRTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Sos1 inhibitors Jul. 18, 2023
-
Patent Title: Kras g12c inhibitors Jan. 10, 2023
-
Patent Title: Mta-cooperative prmt5 inhibitors Nov. 08, 2022
-
Patent Title: Substituted imidazo[1,2-c]pyrimidines as prc2 inhibitors Nov. 01, 2022
-
Patent Title: Mta-cooperative prmt5 inhibitors Oct. 25, 2022
-
Patent Title: Kras g12d inhibitors Sep. 27, 2022
-
Patent Title: Kras g12c inhibitors Mar. 08, 2022
-
Patent Title: Substituted imidazo[1,2-c]pyrimidines as prc2 inhibitors Jan. 11, 2022
-
Patent Title: Substituted imidazo[1,2-c]pyrimidines as prc2 inhibitors Aug. 17, 2021
-
Patent Title: Kras g12c inhibitors Jun. 23, 2020
-
Patent Title: Kras g12c inhibitors May. 12, 2020
-
Patent Title: Ezh2 inhibitors Apr. 23, 2019
-
Patent Title: Lsd1 inhibitors Mar. 19, 2019
-
Patent Title: Kras g12c inhibitors Nov. 13, 2018
-
Patent Title: Lsd1 inhibitors Aug. 28, 2018
-
Patent Title: Lsd1 inhibitors Nov. 07, 2017
Federal grants, loans, and purchases
Followers on MRTX's company Twitter account
Number of mentions of MRTX in WallStreetBets Daily Discussion
Recent insights relating to MRTX
Recent picks made for MRTX stock on CNBC
ETFs with the largest estimated holdings in MRTX
Flights by private jets registered to MRTX